Bioinorganic Chemistry and Applications
Volume 2006 (2006), Article ID 71938, 7 pages
doi:10.1155/BCA/2006/71938
Antihuman Immunodeficiency Virus Type 1 (HIV-1) Activity of Rare Earth Metal Complexes of 4-Hydroxycoumarins in Cell Culture
1Department of Organic Chemistry, Faculty of Pharmacy, Medical University, 2 Dunav Street, Sofia 1000, Bulgaria
2Department of Virology, National Center of Infectious and Parasitic Diseases, 44A Stoletov Street, Sofia 1233, Bulgaria
3Laboratory of Molecular Pathology, Medical University, 2 Zdrave Street, Sofia 1606, Bulgaria
Received 23 December 2004; Revised 9 March 2005; Accepted 17 June 2005
Copyright © 2006 Ilia Manolov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The cerium Ce(III), lanthanum La(III), and neodymium Nd(III) complexes with
4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one (warfarin)
(W) and 3,3′-benzylidenebis[4-hydroxycoumarin]
(1) were synthesized and studied for the first time
for cytotoxicity (on MT-2 cells) and as anti-HIV agents under
acute and chronic infection. The complexes were characterized by different physicochemical methods:
mass spectrometry, ¹H NMR, ¹³C NMR, and IR
spectroscopy. The spectra of the complexes were interpreted on the
basis of comparison with the spectrum of the free ligands.
Anti-HIV effect of the complexes/ligands was measured in MT-2
cells by microtiter infection assay. Detection of endogenous
reverse transcriptase (RT) activity and RT processivity by PCR
indicative for proviral DNA synthesis demonstrated that anti-HIV
activity has not been linked to early stages of viral replication.
No effect on late steps of viral replication has been found using
cells chronically producing HIV-1LAI virus. La(W) demonstrated anti-HIV
activity (IC50=21.4μM) close to maximal
nontoxic concentration. Nd(W), Ce(1), and Nd(1) demonstrated
limited anti-HIV potency, so none of the complexes seems
appropriate to be used in clinic. Further targeting of HIV-1
inhibition by La(W) is under progress.